Covered recipient · General Payments record
MOHAMMED K HASNAIN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Clinical Neurophysiology
General Payments · PY2018–2024
$7,272.74
- Reported across 472 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Education | $221.40 | 4 |
| Food and Beverage | $175.66 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alexion Pharmaceuticals, Inc. | $208.00 | 3 |
| Neurelis, Inc. | $33.63 | 2 |
| ARGENX US, INC. | $29.99 | 2 |
| EMD Serono, Inc. | $23.84 | 1 |
| Lilly USA, LLC | $19.61 | 1 |
| Teva Pharmaceuticals USA, Inc. | $17.49 | 1 |
| Biogen, Inc. | $17.39 | 1 |
| UCB, Inc. | $16.96 | 1 |
| HARMONY BIOSCIENCES LLC | $15.96 | 1 |
| Axsome Therapeutics, Inc. | $14.19 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $8.00 | 02/23/2024 | Education | Undisputed | 01/23/2026 | 1094010736 | CMS |
| Alexion Pharmaceuticals, Inc. | $100.00 | 06/13/2024 | Education | Undisputed | 01/23/2026 | 1093993527 | CMS |
| Alexion Pharmaceuticals, Inc. | $100.00 | 07/24/2024 | Education | Undisputed | 01/23/2026 | 1093916671 | CMS |
| ARGENX US, INC. | $15.04 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142112329 | CMS |
| ARGENX US, INC. | $14.95 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142103340 | CMS |
| Axsome Therapeutics, Inc. | $14.19 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148306872 | CMS |
| Biogen, Inc. | $17.39 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104839320 | CMS |
| EMD Serono, Inc. | $23.84 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120230726 | CMS |
| HARMONY BIOSCIENCES LLC | $15.96 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126068200 | CMS |
| Lilly USA, LLC | $19.61 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135265651 | CMS |
| Neurelis, Inc. | $20.23 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145643198 | CMS |
| Neurelis, Inc. | $13.40 | 09/20/2024 | Education | Undisputed | 01/23/2026 | 1145643200 | CMS |
| Teva Pharmaceuticals USA, Inc. | $17.49 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151543419 | CMS |
| UCB, Inc. | $16.96 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143135731 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.